Moody's confirms Amgen's Baa1 rating; outlook is negative - Moody's

1 min to read

Moody's confirms Amgen's Baa1 rating; outlook is negative – Moody's

Nasdaq Updates Listing Requirements

Throughout 2024, Nasdaq has been revising the procedures for companies dealing with low stock prices, with a focus on cutting...
S-4 – Akari Therapeutics Plc (0001541157) (Filer)

Filed: 2024-09-13 AccNo: 0001193125-24-218968 Size: 28 MB Source: S-4 - Akari Therapeutics Plc (0001541157) (Filer)
Looking Ahead to 2025: Navigating a Shifting D&O Insurance Landscape

In a market known for volatility, public company D&O (directors & officers) insurance has certainly lived up to its reputation...
S-4 – Blue Owl Finance LLC (0002012650) (Filer)

Filed: 2024-09-10 AccNo: 0001193125-24-216704 Size: 5 MB Source: S-4 - Blue Owl Finance LLC (0002012650) (Filer)
S-4 – Blue Owl GP Stakes GP Holdings LLC (0002012652) (Filer)

Filed: 2024-09-10 AccNo: 0001193125-24-216704 Size: 5 MB Source: S-4 - Blue Owl GP Stakes GP Holdings LLC (0002012652) (Filer)